MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company ...

MALVERN, Pa. and TORONTO, Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today ...

Neuronetics (NASDAQ:STIM) reported first-quarter 2026 results that management said were largely in line with expectations, as ...

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker ...

Neuronetics, Inc., a medical technology company focused on mental health, has announced key updates regarding its NeuroStar therapy. The company will be a Silver Sponsor at the 13th Annual Clinical ...

Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% ...

Q1 2026 Management View "Our Q1 results were largely in line with expectations, and we're making progress on the commercial and operational priorities already in motion." (CEO, President & Director ...

MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Neuronetics, which has 203 ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Neuronetics Inc (NASDAQ:STIM) stands against ...

Neuronetics has secured a groundbreaking green light for its noninvasive transcranial magnetic stimulation technology, saying it is now the first to be cleared by the FDA as an add-on therapy for ...